Adenosine - Xsira

Drug Profile

Adenosine - Xsira

Alternative Names: Adenogesic; IV-adenosine

Latest Information Update: 29 Jul 2015

Price : $50

At a glance

  • Originator Harbor-UCLA Research and Education Institute
  • Class Anti-ischaemics; Antiarrhythmics; Purine nucleosides; Ribonucleosides; Small molecules
  • Mechanism of Action Adenosine A1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Postoperative pain

Most Recent Events

  • 31 Oct 2005 Phase-II clinical trials in Postoperative pain in USA (IV)
  • 14 Apr 2005 Clinical trials in Postoperative pain in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top